Balance Sheet
Cash Flow Statement
AmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Change in Working Capital (2016 - 2022)

ProQR Therapeutics' Change in Working Capital history spans 3 years, with the latest figure at $3.5 million for Q3 2022.

  • On a quarterly basis, Change in Working Capital fell 47.64% to $3.5 million in Q3 2022 year-over-year; TTM through Sep 2022 was $3.5 million, a 47.64% decrease, with the full-year FY2023 number at -$52.7 million, down 11554.26% from a year prior.
  • Change in Working Capital hit $3.5 million in Q3 2022 for ProQR Therapeutics, up from -$3.5 million in the prior quarter.
  • Over the last five years, Change in Working Capital for PRQR hit a ceiling of $28.6 million in Q4 2021 and a floor of -$6.5 million in Q4 2020.
  • Historically, Change in Working Capital has averaged $3.2 million across 3 years, with a median of $494020.4 in 2021.
  • Biggest five-year swings in Change in Working Capital: soared 538.11% in 2021 and later tumbled 296.22% in 2022.
  • Tracing PRQR's Change in Working Capital over 3 years: stood at -$6.5 million in 2020, then soared by 538.11% to $28.6 million in 2021, then crashed by 87.78% to $3.5 million in 2022.
  • Business Quant data shows Change in Working Capital for PRQR at $3.5 million in Q3 2022, -$3.5 million in Q2 2022, and -$4.5 million in Q1 2022.